Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
29 mai 2023 19h42 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the...
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
10 mai 2023 16h05 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the...
Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 p.m. EDT
02 mai 2018 07h30 HE
|
Imprimis Pharmaceuticals, Inc.
San Diego, CA, May 02, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release first quarter 2018...